| 益气和胃胶囊 | 自国家药品监督管 理局公告日起七年 | ZYB2072026010 | 合肥立方制药股份 有限公司 | | --- | --- | --- | --- | | 药品品种 | 保护期限 | 保护品种编号 | 企业名称 | 益气和胃胶囊功能主治为健脾和胃，通络止痛。用于慢性非萎缩性胃炎脾胃虚 弱兼胃热瘀阻证，症见胃脘痞满胀痛、食少纳呆、大便溏薄、体倦乏力、舌淡苔薄 黄、脉细。益气和胃胶囊是国家医保和国家基药独家品种，获得多个指南共识推荐， 其处方来源于江苏省名中医、江苏省中医院主任医师单兆伟教授的经验方，临床疗 效确切。 公司益气和胃胶囊获批为国家中药二级保护品种，在保护期内仅限于由获得 《中药保护品种证书》的企业生产，有利于提升公司产品的市场竞争力，对公司产 品的知识产权保护起到积极的影响。由于药品的销售可能受到政策和市场等因素影 响，具有一定的不确定性。敬请广大投资者谨慎决策，注意投资风险。 特此公告。 合肥立方制药股份有限公司 证券代码：003020 证券简称：立方制药 公告编号：2026-007 合肥立方制药股份有限公司 关于益气和胃胶囊获批国家中药保护品种的公告 本公司及董事会全体 ...

接续采购办公室于 2026 年 2 月 27 日发布《关于公布国家组织集采药品协议 期满品种接续采购（LC-YPJX-2026-1）中选结果的通知》，现将相关进展情况公 告如下： | 药品通用名 | 适应症 | 规格包装 | | --- | --- | --- | | 硝苯地平控 | 高血压、冠心病、慢性稳定型心绞痛（劳 | 30mg*28片/盒 | | 释片 | 累性心绞痛）。 | 30mg*14片/盒 | | 盐酸文拉法 | 用于治疗抑郁症（包括伴有焦虑的抑郁 | 75mg(按C₁₇H₂₇NO₂计)*28片/盒 | | 辛缓释片 | 症）及广泛性焦虑障碍。 | 75mg(按C₁₇H₂₇NO₂计)*14片/盒 | | 盐酸曲美他 | 作为添加药物，本品用于对一线抗心绞 | | | 嗪缓释片 | 痛治疗控制不佳或无法耐受的稳定型 | 35mg*30片/盒 | | | 心绞痛成年患者的对症治疗。 | | 一、中选产品情况 证券代码：003020 证券简称：立方制药 公告编号：2026-006 合肥立方制药股份有限公司 关于参加国家组织集采药品协议期满品种接续采购 中选的公告 本公司及董事会全体成员保证信息披露的 ...

Core Viewpoint - Recent developments for Lifan Pharmaceutical (stock code: 003020) focus on product procurement progress and market performance, with three core products expected to enhance sales and market share through national procurement [1] Group 1: Recent Events - Product Procurement Selection: On February 10, 2026, Lifan Pharmaceutical announced that its three products—Nifedipine Controlled-Release Tablets, Venlafaxine Hydrochloride Sustained-Release Tablets, and Trimethoprim Sustained-Release Tablets—are proposed for selection in the national procurement program, which could significantly boost sales and market share [2] - New Drug Application Progress: On the same day, the application for the raw material drug Finerenone was accepted by the National Medical Products Administration, aimed at treating chronic kidney disease related to type 2 diabetes, currently under review [2] Group 2: Stock Performance - Stock Price Movement: Over the past week (February 5 to 11), the stock price fluctuated by 0.84%, with a high of 26.99 yuan on February 6 and a low of 26.22 yuan on February 9. The closing price on February 11 was 26.53 yuan, with a single-day increase of 0.53% and a trading volume of 30.08 million yuan [3] - Capital Flow Situation: On February 11, there was a net outflow of 1.7835 million yuan from institutional investors, while retail investors showed a net inflow, indicating overall stable liquidity [3] Group 3: Sector Performance - Sector Comparison: During the same period, the pharmaceutical and biotechnology sector declined by 0.50%, while Lifan Pharmaceutical's stock performance was slightly better than the sector average [4] Group 4: Institutional Insights - Strategic Transformation Analysis: On February 6, 2026, Morningstar Research noted that Lifan Pharmaceutical is focusing on high-barrier areas such as osmotic pump controlled-release technology and narcotic drugs, with core products like Methylphenidate Hydrochloride Sustained-Release Tablets already on the market. However, short-term performance may experience fluctuations, necessitating attention to new drug volume and balancing R&D investments [5]

证券代码：003020 证券简称：立方制药 公告编号：2026-005 合肥立方制药股份有限公司 关于参加国家组织集采药品协议期满品种接续采购 拟中选的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 合肥立方制药股份有限公司（以下简称"公司"或"立方制药"）于近日参 加了国家组织集采药品协议期满品种接续采购办公室组织的国家组织集采药品 协议期满品种接续采购的投标工作。公司的硝苯地平控释片、盐酸文拉法辛缓释 片、盐酸曲美他嗪缓释片拟中选本次集中采购。现将相关情况公告如下： 合肥立方制药股份有限公司 董事会 一、拟中选产品情况 | 品种名称 | 适应症 | | --- | --- | | 硝苯地平控释片 | 高血压、冠心病、慢性稳定型心绞痛（劳累性心绞痛）。 | | 盐酸文拉法辛缓释片 | 用于治疗抑郁症（包括伴有焦虑的抑郁症）及广泛性焦 | | | 虑障碍。 | | 盐酸曲美他嗪缓释片 | 作为添加药物，本品用于对一线抗心绞痛治疗控制不佳 | | | 或无法耐受的稳定型心绞痛成年患者的对症治疗。 | 二、本次拟中选对公司的影响 本次接续采购品种为第 1-8 ...

Core Viewpoint - The company has received a notice of acceptance for the raw material drug Fenofibrate from the National Medical Products Administration, indicating that the product has entered the registration review stage [1] Group 1 - The acceptance of the raw material drug application signifies that the product is now in the registration review phase [1] - The approval of Fenofibrate would further enrich the company's raw material drug product pipeline [1] - The impact on the company's recent performance is not expected to be significant [1]

Core Viewpoint - The company has received a notice from the National Medical Products Administration regarding the acceptance of the marketing application for Finerenone, a novel non-steroidal selective mineralocorticoid receptor antagonist (MRA) [1] Group 1 - Finerenone is indicated for adult patients with chronic kidney disease associated with type 2 diabetes, aimed at reducing the risk of sustained decline in eGFR and end-stage renal disease [1]

Core Viewpoint - The company, Lifan Pharmaceutical, has received the acceptance notice for the listing application of Finerenone raw material from the National Medical Products Administration, indicating progress in its product development and potential market entry [1] Group 1: Product Information - Finerenone is a novel, non-steroidal, selective mineralocorticoid receptor antagonist (MRA) [1] - The formulation is intended for adult patients with chronic kidney disease associated with type 2 diabetes, aiming to reduce the risk of sustained decline in eGFR and end-stage renal disease [1]

Core Viewpoint - The company, Lifan Pharmaceutical, has received a notice of acceptance for the listing application of Finerenone raw material from the National Medical Products Administration, indicating progress in its product development pipeline [1] Group 1: Product Information - Finerenone is a novel, non-steroidal, selective mineralocorticoid receptor antagonist (MRA) intended for use in adult patients with chronic kidney disease associated with type 2 diabetes, specifically for those with an estimated glomerular filtration rate (eGFR) between 25 to 75 ml/min/1.73m² and albuminuria [1] - The formulation aims to reduce the risk of sustained decline in eGFR and end-stage renal disease [1] Group 2: Market Context - The application pertains to a generic chemical raw material used in already marketed formulations within the country [1] - Among the companies that have registered this raw material, five have an "A" status, indicating approval for use in marketed formulations, while the rest are marked as "I," meaning they have not yet passed the joint review and approval with the formulations [1]

Core Viewpoint - The company has received a notice of acceptance for the listing application of Finerenone raw materials from the National Medical Products Administration, indicating progress in the registration review phase for this new drug [1] Group 1: Product Development - Finerenone is a novel mineralocorticoid receptor antagonist intended for adult patients with type 2 diabetes-related chronic kidney disease [1] - As of the announcement date, five companies have registered the raw material with status "A," while the others are marked as "I" [1] Group 2: Market Impact - The acceptance of the application does not have a significant impact on the company's recent performance, but successful approval could enhance the company's raw material product pipeline [1] - The timeline and outcome of the registration approval remain uncertain, which may pose risks for investors [1]

证券代码：003020 证券简称：立方制药 公告编号：2026-004 合肥立方制药股份有限公司 三、对公司的影响及风险提示 一、《受理通知书》主要内容 申请事项：上市 产品名称：非奈利酮 受理说明：根据《中华人民共和国行政许可法》第三十二条的规定，经审 查，决定予以受理。 登记号：Y20260000042（受理号：CYHS2660116） 二、非奈利酮的相关情况 非奈利酮是一种新型、非甾体类、选择性盐皮质激素受体拮抗剂（MRA）， 其制剂用于与2型糖尿病相关的慢性肾病成人患者（肾小球滤过率估计值[eGFR] ≥25至75ml/min/1.73m2，伴白蛋白尿），可降低eGFR持续下降、终末期肾病的 风险。本次申请属于仿制境内已上市药品所用的化学原料药。截至本公告日， 该品种原料药登记备案的企业中，有5家登记状态为"A"（已批准在上市制剂 使用的原料），其余均为"I"（尚未通过与制剂共同审评审批的原料）。 关于收到原料药上市申请受理通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，合肥立方制药股份有限公司（以下简称"公司"或"立方制药"） 收 ...